FOLH1 and prostate carcinoma: On mice bearing PSMA‐positive prostate cancer xenografts, the biodistributions/dosimetry, tumor growth inhibition, and toxicities were evaluated for the same total injected radioactivity that was delivered by different split ratios between the two carriers.